APO Research
Talk to an analyst

APO RESEARCH · REPORT

Overactive Bladder (OAB) Therapeutics

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Overactive Bladder (OAB) Therapeutics Market Outlook and Growth Opportunities 2026

20 December 2025193 pages

Choose your research edition.

Industry ResearchOveractive Bladder (OAB) Therapeutics Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Overactive Bladder (OAB) Therapeutics Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Overactive Bladder (OAB) Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Overactive Bladder (OAB) Therapeutics Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Overactive Bladder (OAB) Therapeutics Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Overactive Bladder (OAB) Therapeutics market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Overactive Bladder (OAB) Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Overactive Bladder (OAB) Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Overactive Bladder (OAB) Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Overactive Bladder (OAB) Therapeutics market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Overactive Bladder (OAB) Therapeutics market include Allergan, Astellas Pharma, Hisamitsu Pharmaceutical, Ion Channel Innovations, Kwang Dong Pharmaceutical, ONO Pharmaceutical, Tengion, GlaxoSmithKline and Ferring, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Overactive Bladder (OAB) Therapeutics market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Overactive Bladder (OAB) Therapeutics and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Overactive Bladder (OAB) Therapeutics sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Overactive Bladder (OAB) Therapeutics market size, projected growth trends, production technologies, key applications, and end-use industries.

Overactive Bladder (OAB) Therapeutics Segment by Company

Allergan

Astellas Pharma

Hisamitsu Pharmaceutical

Ion Channel Innovations

Kwang Dong Pharmaceutical

ONO Pharmaceutical

Tengion

GlaxoSmithKline

Ferring

Pfizer

Lanzhou Institute of Biological Products

Merck

Sanofi

Teva Pharmaceutical Industries

Overactive Bladder (OAB) Therapeutics Segment by Type

Anticholinergic Agents

Beta-3 Adrenoreceptor Agonists

Overactive Bladder (OAB) Therapeutics Segment by Application

Hosptial

Clinci

Other

Overactive Bladder (OAB) Therapeutics Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Overactive Bladder (OAB) Therapeutics status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Overactive Bladder (OAB) Therapeutics market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Overactive Bladder (OAB) Therapeutics significant trends, drivers, influence factors in global and regions.

6. To analyze Overactive Bladder (OAB) Therapeutics competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Overactive Bladder (OAB) Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Overactive Bladder (OAB) Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Overactive Bladder (OAB) Therapeutics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Overactive Bladder (OAB) Therapeutics market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Overactive Bladder (OAB) Therapeutics industry.

Chapter 3: Detailed analysis of Overactive Bladder (OAB) Therapeutics manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Overactive Bladder (OAB) Therapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Overactive Bladder (OAB) Therapeutics in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Overactive Bladder (OAB) Therapeutics Industry Trends Table 2. Overactive Bladder (OAB) Therapeutics Industry Drivers Table 3. Overactive Bladder (OAB) Therapeutics Industry Opportunities and Challenges Table 4. Overactive Bladder (OAB) Therapeutics Industry Restraints Table 5. Global Overactive Bladder (OAB) Therapeutics Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Overactive Bladder (OAB) Therapeutics Revenue Share by Company (2021-2026) Table 7. Global Overactive Bladder (OAB) Therapeutics Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Overactive Bladder (OAB) Therapeutics Sales Volume Share by Company (2021-2026) Table 9. Global Overactive Bladder (OAB) Therapeutics Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Overactive Bladder (OAB) Therapeutics Company Ranking, (2024-2026) & (USD Million) Table 11. Global Overactive Bladder (OAB) Therapeutics Key Company Manufacturing Base & Headquarters Table 12. Global Overactive Bladder (OAB) Therapeutics Company, Product Type & Application Table 13. Global Overactive Bladder (OAB) Therapeutics Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Overactive Bladder (OAB) Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Anticholinergic Agents Table 18. Significant Companies of Beta-3 Adrenoreceptor Agonists Table 19. Global Overactive Bladder (OAB) Therapeutics Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Overactive Bladder (OAB) Therapeutics Sales Volume by Type (2021-2026) & (K Units) Table 21. Global Overactive Bladder (OAB) Therapeutics Sales Volume by Type (2027-2032) & (K Units) Table 22. Global Overactive Bladder (OAB) Therapeutics Sales Volume Share by Type (2021-2026) Table 23. Global Overactive Bladder (OAB) Therapeutics Sales Volume Share by Type (2027-2032) Table 24. Global Overactive Bladder (OAB) Therapeutics Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Overactive Bladder (OAB) Therapeutics Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Overactive Bladder (OAB) Therapeutics Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Overactive Bladder (OAB) Therapeutics Sales Value Share by Type (2021-2026) Table 28. Global Overactive Bladder (OAB) Therapeutics Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Hosptial Table 30. Significant Companies of Clinci Table 31. Significant Companies of Other Table 32. Global Overactive Bladder (OAB) Therapeutics Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 33. Global Overactive Bladder (OAB) Therapeutics Sales Volume by Application (2021-2026) & (K Units) Table 34. Global Overactive Bladder (OAB) Therapeutics Sales Volume by Application (2027-2032) & (K Units) Table 35. Global Overactive Bladder (OAB) Therapeutics Sales Volume Share by Application (2021-2026) Table 36. Global Overactive Bladder (OAB) Therapeutics Sales Volume Share by Application (2027-2032) Table 37. Global Overactive Bladder (OAB) Therapeutics Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Overactive Bladder (OAB) Therapeutics Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Overactive Bladder (OAB) Therapeutics Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Overactive Bladder (OAB) Therapeutics Sales Value Share by Application (2021-2026) Table 41. Global Overactive Bladder (OAB) Therapeutics Sales Value Share by Application (2027-2032) Table 42. Global Overactive Bladder (OAB) Therapeutics Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 43. Global Overactive Bladder (OAB) Therapeutics Sales by Region (2021-2026) & (K Units) Table 44. Global Overactive Bladder (OAB) Therapeutics Sales Market Share by Region (2021-2026) Table 45. Global Overactive Bladder (OAB) Therapeutics Sales by Region (2027-2032) & (K Units) Table 46. Global Overactive Bladder (OAB) Therapeutics Sales Market Share by Region (2027-2032) Table 47. Global Overactive Bladder (OAB) Therapeutics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Overactive Bladder (OAB) Therapeutics Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Overactive Bladder (OAB) Therapeutics Sales Value Share by Region (2021-2026) Table 50. Global Overactive Bladder (OAB) Therapeutics Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Overactive Bladder (OAB) Therapeutics Sales Value Share by Region (2027-2032) Table 52. Global Overactive Bladder (OAB) Therapeutics Market Average Price (US$/Unit) by Region (2021-2026) Table 53. Global Overactive Bladder (OAB) Therapeutics Market Average Price (US$/Unit) by Region (2027-2032) Table 54. Global Overactive Bladder (OAB) Therapeutics Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Global Overactive Bladder (OAB) Therapeutics Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Overactive Bladder (OAB) Therapeutics Sales by Country (2021-2026) & (K Units) Table 57. Global Overactive Bladder (OAB) Therapeutics Sales Market Share by Country (2021-2026) Table 58. Global Overactive Bladder (OAB) Therapeutics Sales by Country (2027-2032) & (K Units) Table 59. Global Overactive Bladder (OAB) Therapeutics Sales Market Share by Country (2027-2032) Table 60. Global Overactive Bladder (OAB) Therapeutics Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Overactive Bladder (OAB) Therapeutics Sales Value Market Share by Country (2021-2026) Table 62. Global Overactive Bladder (OAB) Therapeutics Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Overactive Bladder (OAB) Therapeutics Sales Value Market Share by Country (2027-2032) Table 64. Allergan Company Information Table 65. Allergan Business Overview Table 66. Allergan Overactive Bladder (OAB) Therapeutics Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 67. Allergan Overactive Bladder (OAB) Therapeutics Product Portfolio Table 68. Allergan Recent Development Table 69. Astellas Pharma Company Information Table 70. Astellas Pharma Business Overview Table 71. Astellas Pharma Overactive Bladder (OAB) Therapeutics Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. Astellas Pharma Overactive Bladder (OAB) Therapeutics Product Portfolio Table 73. Astellas Pharma Recent Development Table 74. Hisamitsu Pharmaceutical Company Information Table 75. Hisamitsu Pharmaceutical Business Overview Table 76. Hisamitsu Pharmaceutical Overactive Bladder (OAB) Therapeutics Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. Hisamitsu Pharmaceutical Overactive Bladder (OAB) Therapeutics Product Portfolio Table 78. Hisamitsu Pharmaceutical Recent Development Table 79. Ion Channel Innovations Company Information Table 80. Ion Channel Innovations Business Overview Table 81. Ion Channel Innovations Overactive Bladder (OAB) Therapeutics Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. Ion Channel Innovations Overactive Bladder (OAB) Therapeutics Product Portfolio Table 83. Ion Channel Innovations Recent Development Table 84. Kwang Dong Pharmaceutical Company Information Table 85. Kwang Dong Pharmaceutical Business Overview Table 86. Kwang Dong Pharmaceutical Overactive Bladder (OAB) Therapeutics Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. Kwang Dong Pharmaceutical Overactive Bladder (OAB) Therapeutics Product Portfolio Table 88. Kwang Dong Pharmaceutical Recent Development Table 89. ONO Pharmaceutical Company Information Table 90. ONO Pharmaceutical Business Overview Table 91. ONO Pharmaceutical Overactive Bladder (OAB) Therapeutics Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. ONO Pharmaceutical Overactive Bladder (OAB) Therapeutics Product Portfolio Table 93. ONO Pharmaceutical Recent Development Table 94. Tengion Company Information Table 95. Tengion Business Overview Table 96. Tengion Overactive Bladder (OAB) Therapeutics Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. Tengion Overactive Bladder (OAB) Therapeutics Product Portfolio Table 98. Tengion Recent Development Table 99. GlaxoSmithKline Company Information Table 100. GlaxoSmithKline Business Overview Table 101. GlaxoSmithKline Overactive Bladder (OAB) Therapeutics Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. GlaxoSmithKline Overactive Bladder (OAB) Therapeutics Product Portfolio Table 103. GlaxoSmithKline Recent Development Table 104. Ferring Company Information Table 105. Ferring Business Overview Table 106. Ferring Overactive Bladder (OAB) Therapeutics Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. Ferring Overactive Bladder (OAB) Therapeutics Product Portfolio Table 108. Ferring Recent Development Table 109. Pfizer Company Information Table 110. Pfizer Business Overview Table 111. Pfizer Overactive Bladder (OAB) Therapeutics Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. Pfizer Overactive Bladder (OAB) Therapeutics Product Portfolio Table 113. Pfizer Recent Development Table 114. Lanzhou Institute of Biological Products Company Information Table 115. Lanzhou Institute of Biological Products Business Overview Table 116. Lanzhou Institute of Biological Products Overactive Bladder (OAB) Therapeutics Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 117. Lanzhou Institute of Biological Products Overactive Bladder (OAB) Therapeutics Product Portfolio Table 118. Lanzhou Institute of Biological Products Recent Development Table 119. Merck Company Information Table 120. Merck Business Overview Table 121. Merck Overactive Bladder (OAB) Therapeutics Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 122. Merck Overactive Bladder (OAB) Therapeutics Product Portfolio Table 123. Merck Recent Development Table 124. Sanofi Company Information Table 125. Sanofi Business Overview Table 126. Sanofi Overactive Bladder (OAB) Therapeutics Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 127. Sanofi Overactive Bladder (OAB) Therapeutics Product Portfolio Table 128. Sanofi Recent Development Table 129. Teva Pharmaceutical Industries Company Information Table 130. Teva Pharmaceutical Industries Business Overview Table 131. Teva Pharmaceutical Industries Overactive Bladder (OAB) Therapeutics Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 132. Teva Pharmaceutical Industries Overactive Bladder (OAB) Therapeutics Product Portfolio Table 133. Teva Pharmaceutical Industries Recent Development Table 134. Key Raw Materials Table 135. Raw Materials Key Suppliers Table 136. Overactive Bladder (OAB) Therapeutics Distributors List Table 137. Overactive Bladder (OAB) Therapeutics Customers List Table 138. Research Programs/Design for This Report Table 139. Authors List of This Report Table 140. Secondary Sources Table 141. Primary Sources List of Figures Figure 1. Overactive Bladder (OAB) Therapeutics Product Image Figure 2. Global Overactive Bladder (OAB) Therapeutics Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Overactive Bladder (OAB) Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 4. Global Overactive Bladder (OAB) Therapeutics Sales (2021-2032) & (K Units) Figure 5. Global Overactive Bladder (OAB) Therapeutics Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Overactive Bladder (OAB) Therapeutics Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Anticholinergic Agents Image Figure 10. Beta-3 Adrenoreceptor Agonists Image Figure 11. Global Overactive Bladder (OAB) Therapeutics Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Overactive Bladder (OAB) Therapeutics Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Overactive Bladder (OAB) Therapeutics Sales Volume Share by Type (2021-2032) Figure 14. Global Overactive Bladder (OAB) Therapeutics Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Overactive Bladder (OAB) Therapeutics Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Overactive Bladder (OAB) Therapeutics Sales Value Share by Type (2021-2032) Figure 17. Hosptial Image Figure 18. Clinci Image Figure 19. Other Image Figure 20. Global Overactive Bladder (OAB) Therapeutics Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 21. Global Overactive Bladder (OAB) Therapeutics Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Overactive Bladder (OAB) Therapeutics Sales Volume Share by Application (2021-2032) Figure 23. Global Overactive Bladder (OAB) Therapeutics Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Overactive Bladder (OAB) Therapeutics Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Overactive Bladder (OAB) Therapeutics Sales Value Share by Application (2021-2032) Figure 26. Global Overactive Bladder (OAB) Therapeutics Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 27. Global Overactive Bladder (OAB) Therapeutics Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Overactive Bladder (OAB) Therapeutics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Overactive Bladder (OAB) Therapeutics Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Overactive Bladder (OAB) Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 31. North America Overactive Bladder (OAB) Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Overactive Bladder (OAB) Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Overactive Bladder (OAB) Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Overactive Bladder (OAB) Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Overactive Bladder (OAB) Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Overactive Bladder (OAB) Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 37. South America Overactive Bladder (OAB) Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Overactive Bladder (OAB) Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Overactive Bladder (OAB) Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Overactive Bladder (OAB) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Overactive Bladder (OAB) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Overactive Bladder (OAB) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Overactive Bladder (OAB) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Overactive Bladder (OAB) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Overactive Bladder (OAB) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Overactive Bladder (OAB) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Overactive Bladder (OAB) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Overactive Bladder (OAB) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Overactive Bladder (OAB) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Overactive Bladder (OAB) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Overactive Bladder (OAB) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Overactive Bladder (OAB) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Overactive Bladder (OAB) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Overactive Bladder (OAB) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Overactive Bladder (OAB) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Overactive Bladder (OAB) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Overactive Bladder (OAB) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Overactive Bladder (OAB) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Overactive Bladder (OAB) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Overactive Bladder (OAB) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Overactive Bladder (OAB) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Overactive Bladder (OAB) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Overactive Bladder (OAB) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Overactive Bladder (OAB) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Overactive Bladder (OAB) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Overactive Bladder (OAB) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Overactive Bladder (OAB) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Overactive Bladder (OAB) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Overactive Bladder (OAB) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Overactive Bladder (OAB) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Overactive Bladder (OAB) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Overactive Bladder (OAB) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Overactive Bladder (OAB) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Overactive Bladder (OAB) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Overactive Bladder (OAB) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Overactive Bladder (OAB) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Overactive Bladder (OAB) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Overactive Bladder (OAB) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Overactive Bladder (OAB) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Overactive Bladder (OAB) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Overactive Bladder (OAB) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Overactive Bladder (OAB) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Overactive Bladder (OAB) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Overactive Bladder (OAB) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Overactive Bladder (OAB) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Overactive Bladder (OAB) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Overactive Bladder (OAB) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Overactive Bladder (OAB) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Overactive Bladder (OAB) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Overactive Bladder (OAB) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Overactive Bladder (OAB) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Overactive Bladder (OAB) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Overactive Bladder (OAB) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Overactive Bladder (OAB) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Overactive Bladder (OAB) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Overactive Bladder (OAB) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Overactive Bladder (OAB) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Overactive Bladder (OAB) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Overactive Bladder (OAB) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Overactive Bladder (OAB) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Overactive Bladder (OAB) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Overactive Bladder (OAB) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Overactive Bladder (OAB) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Overactive Bladder (OAB) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Overactive Bladder (OAB) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Overactive Bladder (OAB) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Overactive Bladder (OAB) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Overactive Bladder (OAB) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Overactive Bladder (OAB) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Overactive Bladder (OAB) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Overactive Bladder (OAB) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Overactive Bladder (OAB) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Overactive Bladder (OAB) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Overactive Bladder (OAB) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Overactive Bladder (OAB) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Overactive Bladder (OAB) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Overactive Bladder (OAB) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Overactive Bladder (OAB) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Overactive Bladder (OAB) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Overactive Bladder (OAB) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Overactive Bladder (OAB) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Overactive Bladder (OAB) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Overactive Bladder (OAB) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Overactive Bladder (OAB) Therapeutics Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Overactive Bladder (OAB) Therapeutics Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Anticholinergic Agents
  • Beta-3 Adrenoreceptor Agonists
Applications
  • Hosptial
  • Clinci
  • Other
Companies covered
  • Allergan
  • Astellas Pharma
  • Hisamitsu Pharmaceutical
  • Ion Channel Innovations
  • Kwang Dong Pharmaceutical
  • ONO Pharmaceutical
  • Tengion
  • GlaxoSmithKline
  • Ferring
  • Pfizer
  • Lanzhou Institute of Biological Products
  • Merck
  • Sanofi
  • Teva Pharmaceutical Industries

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Overactive Bladder (OAB) Therapeutics Sales Value (2021-2032)
  4. 1.2.2 Global Overactive Bladder (OAB) Therapeutics Sales Volume (2021-2032)
  5. 1.2.3 Global Overactive Bladder (OAB) Therapeutics Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Overactive Bladder (OAB) Therapeutics Market Dynamics
  1. 2.1 Overactive Bladder (OAB) Therapeutics Industry Trends
  2. 2.2 Overactive Bladder (OAB) Therapeutics Industry Drivers
  3. 2.3 Overactive Bladder (OAB) Therapeutics Industry Opportunities and Challenges
  4. 2.4 Overactive Bladder (OAB) Therapeutics Industry Restraints
3 Overactive Bladder (OAB) Therapeutics Market by Company
  1. 3.1 Global Overactive Bladder (OAB) Therapeutics Company Revenue Ranking in 2025
  2. 3.2 Global Overactive Bladder (OAB) Therapeutics Revenue by Company (2021-2026)
  3. 3.3 Global Overactive Bladder (OAB) Therapeutics Sales Volume by Company (2021-2026)
  4. 3.4 Global Overactive Bladder (OAB) Therapeutics Average Price by Company (2021-2026)
  5. 3.5 Global Overactive Bladder (OAB) Therapeutics Company Ranking (2024-2026)
  6. 3.6 Global Overactive Bladder (OAB) Therapeutics Company Manufacturing Base and Headquarters
  7. 3.7 Global Overactive Bladder (OAB) Therapeutics Company Product Type and Application
  8. 3.8 Global Overactive Bladder (OAB) Therapeutics Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Overactive Bladder (OAB) Therapeutics Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Overactive Bladder (OAB) Therapeutics Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Overactive Bladder (OAB) Therapeutics Market by Type
  1. 4.1 Overactive Bladder (OAB) Therapeutics Type Introduction
  2. 4.1.1 Anticholinergic Agents
  3. 4.1.2 Beta-3 Adrenoreceptor Agonists
  4. 4.2 Global Overactive Bladder (OAB) Therapeutics Sales Volume by Type
  5. 4.2.1 Global Overactive Bladder (OAB) Therapeutics Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Overactive Bladder (OAB) Therapeutics Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Overactive Bladder (OAB) Therapeutics Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Overactive Bladder (OAB) Therapeutics Sales Value by Type
  9. 4.3.1 Global Overactive Bladder (OAB) Therapeutics Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Overactive Bladder (OAB) Therapeutics Sales Value by Type (2021-2032)
  11. 4.3.3 Global Overactive Bladder (OAB) Therapeutics Sales Value Share by Type (2021-2032)
5 Overactive Bladder (OAB) Therapeutics Market by Application
  1. 5.1 Overactive Bladder (OAB) Therapeutics Application Introduction
  2. 5.1.1 Hosptial
  3. 5.1.2 Clinci
  4. 5.1.3 Other
  5. 5.2 Global Overactive Bladder (OAB) Therapeutics Sales Volume by Application
  6. 5.2.1 Global Overactive Bladder (OAB) Therapeutics Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Overactive Bladder (OAB) Therapeutics Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Overactive Bladder (OAB) Therapeutics Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Overactive Bladder (OAB) Therapeutics Sales Value by Application
  10. 5.3.1 Global Overactive Bladder (OAB) Therapeutics Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Overactive Bladder (OAB) Therapeutics Sales Value by Application (2021-2032)
  12. 5.3.3 Global Overactive Bladder (OAB) Therapeutics Sales Value Share by Application (2021-2032)
6 Overactive Bladder (OAB) Therapeutics Regional Sales and Value Analysis
  1. 6.1 Global Overactive Bladder (OAB) Therapeutics Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Overactive Bladder (OAB) Therapeutics Sales by Region (2021-2032)
  3. 6.2.1 Global Overactive Bladder (OAB) Therapeutics Sales by Region: 2021-2026
  4. 6.2.2 Global Overactive Bladder (OAB) Therapeutics Sales by Region (2027-2032)
  5. 6.3 Global Overactive Bladder (OAB) Therapeutics Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Overactive Bladder (OAB) Therapeutics Sales Value by Region (2021-2032)
  7. 6.4.1 Global Overactive Bladder (OAB) Therapeutics Sales Value by Region: 2021-2026
  8. 6.4.2 Global Overactive Bladder (OAB) Therapeutics Sales Value by Region (2027-2032)
  9. 6.5 Global Overactive Bladder (OAB) Therapeutics Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Overactive Bladder (OAB) Therapeutics Sales Value (2021-2032)
  12. 6.6.2 North America Overactive Bladder (OAB) Therapeutics Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Overactive Bladder (OAB) Therapeutics Sales Value (2021-2032)
  15. 6.7.2 Europe Overactive Bladder (OAB) Therapeutics Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Overactive Bladder (OAB) Therapeutics Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Overactive Bladder (OAB) Therapeutics Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Overactive Bladder (OAB) Therapeutics Sales Value (2021-2032)
  21. 6.9.2 South America Overactive Bladder (OAB) Therapeutics Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Overactive Bladder (OAB) Therapeutics Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Overactive Bladder (OAB) Therapeutics Sales Value Share by Country, 2025 VS 2032
7 Overactive Bladder (OAB) Therapeutics Country-level Sales and Value Analysis
  1. 7.1 Global Overactive Bladder (OAB) Therapeutics Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Overactive Bladder (OAB) Therapeutics Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Overactive Bladder (OAB) Therapeutics Sales by Country (2021-2032)
  4. 7.3.1 Global Overactive Bladder (OAB) Therapeutics Sales by Country (2021-2026)
  5. 7.3.2 Global Overactive Bladder (OAB) Therapeutics Sales by Country (2027-2032)
  6. 7.4 Global Overactive Bladder (OAB) Therapeutics Sales Value by Country (2021-2032)
  7. 7.4.1 Global Overactive Bladder (OAB) Therapeutics Sales Value by Country (2021-2026)
  8. 7.4.2 Global Overactive Bladder (OAB) Therapeutics Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Overactive Bladder (OAB) Therapeutics Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Overactive Bladder (OAB) Therapeutics Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Overactive Bladder (OAB) Therapeutics Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Overactive Bladder (OAB) Therapeutics Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Overactive Bladder (OAB) Therapeutics Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Overactive Bladder (OAB) Therapeutics Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Overactive Bladder (OAB) Therapeutics Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Overactive Bladder (OAB) Therapeutics Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Overactive Bladder (OAB) Therapeutics Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Overactive Bladder (OAB) Therapeutics Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Overactive Bladder (OAB) Therapeutics Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Overactive Bladder (OAB) Therapeutics Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Overactive Bladder (OAB) Therapeutics Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Overactive Bladder (OAB) Therapeutics Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Overactive Bladder (OAB) Therapeutics Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Overactive Bladder (OAB) Therapeutics Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Overactive Bladder (OAB) Therapeutics Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Overactive Bladder (OAB) Therapeutics Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Overactive Bladder (OAB) Therapeutics Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Overactive Bladder (OAB) Therapeutics Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Overactive Bladder (OAB) Therapeutics Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Overactive Bladder (OAB) Therapeutics Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Overactive Bladder (OAB) Therapeutics Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Overactive Bladder (OAB) Therapeutics Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Overactive Bladder (OAB) Therapeutics Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Overactive Bladder (OAB) Therapeutics Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Overactive Bladder (OAB) Therapeutics Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Overactive Bladder (OAB) Therapeutics Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Overactive Bladder (OAB) Therapeutics Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Overactive Bladder (OAB) Therapeutics Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Overactive Bladder (OAB) Therapeutics Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Overactive Bladder (OAB) Therapeutics Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Overactive Bladder (OAB) Therapeutics Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Overactive Bladder (OAB) Therapeutics Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Overactive Bladder (OAB) Therapeutics Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Overactive Bladder (OAB) Therapeutics Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Overactive Bladder (OAB) Therapeutics Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Overactive Bladder (OAB) Therapeutics Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Overactive Bladder (OAB) Therapeutics Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Overactive Bladder (OAB) Therapeutics Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Overactive Bladder (OAB) Therapeutics Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Overactive Bladder (OAB) Therapeutics Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Overactive Bladder (OAB) Therapeutics Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Overactive Bladder (OAB) Therapeutics Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Overactive Bladder (OAB) Therapeutics Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Overactive Bladder (OAB) Therapeutics Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Overactive Bladder (OAB) Therapeutics Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Overactive Bladder (OAB) Therapeutics Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Overactive Bladder (OAB) Therapeutics Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Overactive Bladder (OAB) Therapeutics Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Overactive Bladder (OAB) Therapeutics Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Overactive Bladder (OAB) Therapeutics Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Overactive Bladder (OAB) Therapeutics Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Overactive Bladder (OAB) Therapeutics Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Overactive Bladder (OAB) Therapeutics Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Overactive Bladder (OAB) Therapeutics Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Overactive Bladder (OAB) Therapeutics Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Overactive Bladder (OAB) Therapeutics Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Overactive Bladder (OAB) Therapeutics Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Overactive Bladder (OAB) Therapeutics Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Overactive Bladder (OAB) Therapeutics Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Overactive Bladder (OAB) Therapeutics Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Overactive Bladder (OAB) Therapeutics Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Overactive Bladder (OAB) Therapeutics Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Overactive Bladder (OAB) Therapeutics Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Overactive Bladder (OAB) Therapeutics Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Overactive Bladder (OAB) Therapeutics Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Overactive Bladder (OAB) Therapeutics Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Overactive Bladder (OAB) Therapeutics Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Overactive Bladder (OAB) Therapeutics Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Overactive Bladder (OAB) Therapeutics Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Overactive Bladder (OAB) Therapeutics Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Overactive Bladder (OAB) Therapeutics Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Overactive Bladder (OAB) Therapeutics Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Overactive Bladder (OAB) Therapeutics Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Overactive Bladder (OAB) Therapeutics Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Overactive Bladder (OAB) Therapeutics Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Overactive Bladder (OAB) Therapeutics Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Overactive Bladder (OAB) Therapeutics Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Overactive Bladder (OAB) Therapeutics Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Overactive Bladder (OAB) Therapeutics Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Overactive Bladder (OAB) Therapeutics Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Overactive Bladder (OAB) Therapeutics Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Overactive Bladder (OAB) Therapeutics Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Allergan
  2. 8.1.1 Allergan Company Information
  3. 8.1.2 Allergan Business Overview
  4. 8.1.3 Allergan Overactive Bladder (OAB) Therapeutics Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Allergan Overactive Bladder (OAB) Therapeutics Product Portfolio
  6. 8.1.5 Allergan Recent Developments
  7. 8.2 Astellas Pharma
  8. 8.2.1 Astellas Pharma Company Information
  9. 8.2.2 Astellas Pharma Business Overview
  10. 8.2.3 Astellas Pharma Overactive Bladder (OAB) Therapeutics Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Astellas Pharma Overactive Bladder (OAB) Therapeutics Product Portfolio
  12. 8.2.5 Astellas Pharma Recent Developments
  13. 8.3 Hisamitsu Pharmaceutical
  14. 8.3.1 Hisamitsu Pharmaceutical Company Information
  15. 8.3.2 Hisamitsu Pharmaceutical Business Overview
  16. 8.3.3 Hisamitsu Pharmaceutical Overactive Bladder (OAB) Therapeutics Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Hisamitsu Pharmaceutical Overactive Bladder (OAB) Therapeutics Product Portfolio
  18. 8.3.5 Hisamitsu Pharmaceutical Recent Developments
  19. 8.4 Ion Channel Innovations
  20. 8.4.1 Ion Channel Innovations Company Information
  21. 8.4.2 Ion Channel Innovations Business Overview
  22. 8.4.3 Ion Channel Innovations Overactive Bladder (OAB) Therapeutics Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Ion Channel Innovations Overactive Bladder (OAB) Therapeutics Product Portfolio
  24. 8.4.5 Ion Channel Innovations Recent Developments
  25. 8.5 Kwang Dong Pharmaceutical
  26. 8.5.1 Kwang Dong Pharmaceutical Company Information
  27. 8.5.2 Kwang Dong Pharmaceutical Business Overview
  28. 8.5.3 Kwang Dong Pharmaceutical Overactive Bladder (OAB) Therapeutics Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Kwang Dong Pharmaceutical Overactive Bladder (OAB) Therapeutics Product Portfolio
  30. 8.5.5 Kwang Dong Pharmaceutical Recent Developments
  31. 8.6 ONO Pharmaceutical
  32. 8.6.1 ONO Pharmaceutical Company Information
  33. 8.6.2 ONO Pharmaceutical Business Overview
  34. 8.6.3 ONO Pharmaceutical Overactive Bladder (OAB) Therapeutics Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 ONO Pharmaceutical Overactive Bladder (OAB) Therapeutics Product Portfolio
  36. 8.6.5 ONO Pharmaceutical Recent Developments
  37. 8.7 Tengion
  38. 8.7.1 Tengion Company Information
  39. 8.7.2 Tengion Business Overview
  40. 8.7.3 Tengion Overactive Bladder (OAB) Therapeutics Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Tengion Overactive Bladder (OAB) Therapeutics Product Portfolio
  42. 8.7.5 Tengion Recent Developments
  43. 8.8 GlaxoSmithKline
  44. 8.8.1 GlaxoSmithKline Company Information
  45. 8.8.2 GlaxoSmithKline Business Overview
  46. 8.8.3 GlaxoSmithKline Overactive Bladder (OAB) Therapeutics Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 GlaxoSmithKline Overactive Bladder (OAB) Therapeutics Product Portfolio
  48. 8.8.5 GlaxoSmithKline Recent Developments
  49. 8.9 Ferring
  50. 8.9.1 Ferring Company Information
  51. 8.9.2 Ferring Business Overview
  52. 8.9.3 Ferring Overactive Bladder (OAB) Therapeutics Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Ferring Overactive Bladder (OAB) Therapeutics Product Portfolio
  54. 8.9.5 Ferring Recent Developments
  55. 8.10 Pfizer
  56. 8.10.1 Pfizer Company Information
  57. 8.10.2 Pfizer Business Overview
  58. 8.10.3 Pfizer Overactive Bladder (OAB) Therapeutics Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Pfizer Overactive Bladder (OAB) Therapeutics Product Portfolio
  60. 8.10.5 Pfizer Recent Developments
  61. 8.11 Lanzhou Institute of Biological Products
  62. 8.11.1 Lanzhou Institute of Biological Products Company Information
  63. 8.11.2 Lanzhou Institute of Biological Products Business Overview
  64. 8.11.3 Lanzhou Institute of Biological Products Overactive Bladder (OAB) Therapeutics Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Lanzhou Institute of Biological Products Overactive Bladder (OAB) Therapeutics Product Portfolio
  66. 8.11.5 Lanzhou Institute of Biological Products Recent Developments
  67. 8.12 Merck
  68. 8.12.1 Merck Company Information
  69. 8.12.2 Merck Business Overview
  70. 8.12.3 Merck Overactive Bladder (OAB) Therapeutics Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Merck Overactive Bladder (OAB) Therapeutics Product Portfolio
  72. 8.12.5 Merck Recent Developments
  73. 8.13 Sanofi
  74. 8.13.1 Sanofi Company Information
  75. 8.13.2 Sanofi Business Overview
  76. 8.13.3 Sanofi Overactive Bladder (OAB) Therapeutics Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Sanofi Overactive Bladder (OAB) Therapeutics Product Portfolio
  78. 8.13.5 Sanofi Recent Developments
  79. 8.14 Teva Pharmaceutical Industries
  80. 8.14.1 Teva Pharmaceutical Industries Company Information
  81. 8.14.2 Teva Pharmaceutical Industries Business Overview
  82. 8.14.3 Teva Pharmaceutical Industries Overactive Bladder (OAB) Therapeutics Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Teva Pharmaceutical Industries Overactive Bladder (OAB) Therapeutics Product Portfolio
  84. 8.14.5 Teva Pharmaceutical Industries Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Overactive Bladder (OAB) Therapeutics Value Chain Analysis
  2. 9.1.1 Overactive Bladder (OAB) Therapeutics Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Overactive Bladder (OAB) Therapeutics Sales Mode & Process
  6. 9.2 Overactive Bladder (OAB) Therapeutics Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Overactive Bladder (OAB) Therapeutics Distributors
  9. 9.2.3 Overactive Bladder (OAB) Therapeutics Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst